#Japan #Newark #ACROBiosystems #PMDA #IL-15

ACROBiosystems Achieves PMDA Material Suitability Confirmation for GMP-grade IL-15

In a significant advancement for the biopharmaceutical sector, ACROBiosystems has formally received the PMDA's Material Suitability Confirmation for its GMP-grade Human IL-15 protein. This recognition, granted by Japan's Pharmaceuticals and Medical Devices Agency (PMDA), is a testament to the company's unwavering commitment to quality and compliance in the development of regenerative medicine products, particularly those related to cell and gene therapy.

Understanding PMDA Material Suitability Confirmation

The PMDA operates a rigorous evaluation system designed specifically for key raw materials utilized in regenerative medical products, including CAR-T, CAR-NK, and TCR-T immunotherapies. The primary aim of obtaining this confirmation is for developers to gain assurance regarding the safety and compliance of raw materials at the early stages of their research and development processes. By securing this confirmation, ACROBiosystems has simplified the journey for developers applying for clinical trials or marketing approvals, thereby expediting the overall product development timeline.

To obtain this confirmation, ACROBiosystems had to meet several stringent criteria, which include ensuring that the product and its manufacturing processes exclude human or animal-derived components that necessitate compliance proof with the Biological Raw Materials guidelines. Moreover, the product must not contain any physiologically active substances, toxic elements, heavy metals, or components that could compromise the safety of clinical trial products. An effective quality management system that offers complete traceability and validation of testing data throughout the production process is also crucial.

The confirmation explicitly states that ACROBiosystems employs no human or animal-derived components in the formulation and preparation of its IL-15 protein. This GMP-grade product includes recombinant human IL-15 at a concentration of 0.3 g/L, meeting the rigorous safety evaluation requirements set forth by the PMDA.

Significance of IL-15 in Cell Therapies

As a pivotal cytokine, IL-15 plays an instrumental role in promoting high-quality immune cell cultures and functional validations in vitro. It is crucial for the development of various adoptive cell therapies, such as CAR-T, CAR-NK, and TCR-T therapies. The fact that ACROBiosystems' IL-15 product has successfully met the PMDA certification reflects its robust GMP production system, which is specifically designed without any animal-derived components and is backed by comprehensive functional validation data.

ACROBiosystems' IL-15 product can efficiently activate key signaling pathways in immune cells, namely the JAK-STAT and PI3K-AKT pathways. This activity significantly boosts the cytotoxicity and persistence of both T cells and natural killer cells in vivo, ultimately enhancing anti-tumor immune memory and mitigating cell exhaustion. Additionally, it supports the expansion of high-quality cell subpopulations, such as stem cell-like memory T cells (Tscm) and long-lived memory NK cells.

Enabling Faster Drug Development

With PMDA's confirmation, ACROBiosystems is well-positioned to assist clients in Japan significantly streamline their evaluation process concerning cell therapy raw materials. Developers of cell therapies leveraging this IL-15 product can directly utilize this endorsement, thus shortening the timeline from research and development to clinical trials. In securing such recognition from PMDA—a globally respected authority along with the FDA and EMA—ACROBiosystems reaffirms its dedication to upholding the highest standards of quality essential for biopharmaceutical advancement.

Beyond Japan, the company has established comprehensive regulatory support capabilities across major global markets. All its GMP products are compliant with DMF filing requirements in the United States. For regions like China and Europe, where official pathways for GMP raw material filings are still being established, ACROBiosystems continues to offer detailed RSF (Regulatory Support File) documentation to aid in international drug application processes.

Having assisted around 30 clients in meeting regulatory requirements across China, the United States, and South Korea demonstrates ACROBiosystems' vast experience and reliability in this domain. The company's strategic prioritization of stringent quality management measures is crucial for ensuring product and service excellence, thereby facilitating accelerated biopharmaceutical development.

Since its inception, ACROBiosystems has continuously enhanced its quality management frameworks. First receiving ISO 9001 certification in 2016, followed by ISO 13485 in 2018, the company established a GMP quality management system in 2021. Its production site in Suzhou achieved dual ISO 9001 and GMP certification in 2024.

The company's committed quality management team is highly proficient in navigating varied biopharmaceutical regulations across different regions, actively keeping pace with industry advancements to bolster the efficacy of their quality management systems.

In conclusion, ACROBiosystems Group remains dedicated to providing partners with premium-grade products complemented by extensive regulatory support documentation, thereby ensuring a smoother pharmaceutical approval process for groundbreaking therapies. The company embodies a driving force in the biopharmaceutical landscape, fostering innovation and global health advancement.